Literature DB >> 6157048

Patterns of urinary beta 2-microglobulin excretion by patients treated with aminoglycosides.

J J Schentag, M E Plaut.   

Abstract

Aminoglycoside antibiotics are relatively mild nephrotoxins, but their action is site-specific to the proximal tubule. Therefore, use of these drugs presents a unique opportunity to study the temporal relation between the damage to the cells lining the renal proximal tubule and the subsequent rise in the serum creatinine concentration. Our study of 52 aminoglycoside-treated patients included measurements of daily serum creatinine, daily 24-hour urinary beta 2-microglobulin (beta 2M) excretion, and determination of aminoglycoside tissue accumulation. An elevation in beta 2M excretion above the baseline value occurred in 37 of 52 (71%), whereas the serum creatinine concentration rose in only 17 of 52 (33%) of patients. Even fewer patients (10 of 52) demonstrated all three criteria for aminoglycoside nephrotoxicity. These 10 patients had elevated tissue accumulation, evidence of renal tubular damage, and a rise in serum creatinine concentration. The increased beta 2M excretion greater than 50 mg/day preceded the serum creatinine rise by 2 to 7 days. An abnormal baseline beta 2M was not a risk factor for a subsequent rise in creatinine concentration or vice versa. Although each test is primarily site specific, widespread and severe renal proximal tubular damage, regardless of cause, will eventually lead to an elevation of serum creatinine. Thus, serial monitoring of proximal tubular function with urinary beta 2M excretion has potential value in the assessment of insults to this site, but cannot be expected to explain all changes in serum creatinine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6157048     DOI: 10.1038/ki.1980.77

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  14 in total

1.  Urinary beta 2-microglobulin as an indicator of proximal renal tubular dysfunction in asphyxiated full-term newborns.

Authors:  M el-Mauhoub; J Kishan; O P Jaiswal; A A Asbali; N el houni
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

Review 2.  Biomarkers of Drug-Induced Kidney Toxicity.

Authors:  Benjamin R Griffin; Sarah Faubel; Charles L Edelstein
Journal:  Ther Drug Monit       Date:  2019-04       Impact factor: 3.681

Review 3.  Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations.

Authors:  K Mörike; M Schwab; U Klotz
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 4.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

5.  Renal tubular enzyme effects of clarithromycin in comparison with gentamicin and placebo in volunteers.

Authors:  M C Chapelsky; D E Nix; J C Cavanaugh; J H Wilton; A Norman; J J Schentag
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 6.  Biomarkers of nephrotoxic acute kidney injury.

Authors:  Michael A Ferguson; Vishal S Vaidya; Joseph V Bonventre
Journal:  Toxicology       Date:  2008-01-04       Impact factor: 4.221

7.  Experience with brulamycin therapy in dialysed patients.

Authors:  L Löcsey; E Faragó; G Kakuk
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

8.  Multiple-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects.

Authors:  E A Swabb; A A Sugerman; D N McKinstry
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

9.  Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients.

Authors:  J J Schentag; M E Plaut; F B Cerra
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

10.  A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis.

Authors:  J J Schentag; P B Wels; D P Reitberg; P Walczak; J H Van Tyle; R J Lascola
Journal:  Ann Surg       Date:  1983-07       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.